{"id":"NCT00453986","sponsor":"GlaxoSmithKline","briefTitle":"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","officialTitle":"Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the Co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04-09","primaryCompletion":"2007-11-30","completion":"2008-05-21","firstPosted":"2007-03-29","resultsPosted":"2012-05-22","lastUpdate":"2018-09-25"},"enrollment":1352,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]},{"type":"BIOLOGICAL","name":"Mencevax™ACWY","otherNames":[]},{"type":"BIOLOGICAL","name":"Fluarix™","otherNames":[]}],"arms":[{"label":"Nimenrix A Group","type":"EXPERIMENTAL"},{"label":"Nimenrix B Group","type":"EXPERIMENTAL"},{"label":"Nimenrix C Group","type":"EXPERIMENTAL"},{"label":"Mencevax ACWY Group","type":"ACTIVE_COMPARATOR"},{"label":"Nimenrix+Fluarix Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate, in 18-55 year old adults, the consistency of different manufactured lots of meningococcal vaccine GSK134612, the non-inferiority of GSK134612 compared to licensed meningococcal vaccine Mencevax™, the non-inferiority of GSK134612 when given in an experimental co-administration with Fluarix™ compared to GSK134612 given alone and the immunogenicity of GSK134612 given with Fluarix™.\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Serum Bactericidal Assay (Performed Using Baby Rabbit Complement) for Neisseria Meningitidis Serogroups A, C, W-135 and Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers, in Each of the 3 Lot Groups.","timeFrame":"One month after vaccination (at Month 1)","effectByArm":[{"arm":"Nimenrix A Group","deltaMin":3913.1,"sd":null},{"arm":"Nimenrix B Group","deltaMin":3503.5,"sd":null},{"arm":"Nimenrix C Group","deltaMin":3470.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":4,"countries":["Lebanon","Philippines"]},"refs":{"pmids":["22485050","22485048"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":935},"commonTop":["Pain","Headache","Fatigue","Redness","Swelling"]}}